Table 3.

Treatment-related serious adverse events (SAEs) that were reported in patients in the GB242 and INF group, # (%)

Treatment-related SAEs	GB242 (N = 283) n (%)	INF (N = 283) n (%)	Total (N = 566) n (%)
Any treatment-related SAEs, patients (%)	10 (3.5%)	12 (4.2%)	22 (3.9%)
Lung infection	2 (0.7%)	1 (0.4%)	3 (0.5%)
Shingles	1 (0.4%)	0	1 (0.2%)
Cryptococcal pneumonia	1 (0.4%)	0	1 (0.2%)
Drug-induced hypersensitivity	1 (0.4%)	0	1 (0.2%)
Immediate anaphylactic shock	1 (0.4%)	0	1 (0.2%)
Decreased oral sensation	1 (0.4%)	0	1 (0.2%)
gastritis	1 (0.4%)	0	1 (0.2%)
Lung inflammation	1 (0.4%)	1 (0.4%)	2 (0.4%)
Liver damage	1 (0.4%)	0	1 (0.2%)
Upper respiratory tract infection	0	1 (0.4%)	1 (0.2%)
Lymph node tuberculosis	0	1 (0.4%)	1 (0.2%)
Gastroenteritis	0	1 (0.4%)	1 (0.2%)
Hematopoietic lymphohistiocytosis	0	1 (0.4%)	1 (0.2%)
Cough	0	1 (0.4%)	1 (0.2%)
Expectoration	0	1 (0.4%)	1 (0.2%)
Interstitial lung disease	0	1 (0.4%)	1 (0.2%)
Fever	0	1 (0.4%)	1 (0.2%)
Polyserositis	0	1 (0.4%)	1 (0.2%)
Lupus-like syndrome	0	1 (0.4%)	1 (0.2%)
Sinus bradycardia	0	1 (0.4%)	1 (0.2%)
Erythema nodosa	0	1 (0.4%)	1 (0.2%)
Anemia	0	1 (0.4%)	1 (0.2%)